Roche and Korea BIO offers opportunity to domestic companies

for technology transfer and cooperation to advance abroad

Will hold an online and offline open innovation event on the 9th of next month

Will accept applications and conduct reviews until the 24th

KoreaBIO and Roche are hosting an open innovation event(Pic: KoreaBIO)

The Korea Biotechnology Industry Organization will be providing opportunities for technology transfer and overseas expansion of domestic biopharmaceutical companies.

 

For this purpose, Korea Bio plans to first cooperate with the multinational pharmaceutical company Roche.

 

According to industry sources on the 10th, Korea BIO is planning to hold a ‘Korea BIO x Roche Partnering’ open innovation event on the 9th of next month.

 

The event will be held on and offline at Roche Korea’s head office in Gangnam, Seoul, and be attended by groups wishing to partner with Roche.

 

The event will offer one-on-one meetings between global pharmaceutical companies and domestic biopharmaceutical companies.

 

Korea BIO planned the event to provide opportunities for domestic pharmaceutical and biohealth companies to receive a diagnosis on their commercialization potential for technology transfer and overseas expansion, etc.

 

Domestic pharmaceutical and biohealth companies wishing to engage in technology transfer and joint research with Roche can submit an application, and prepare nonconfidential company introduction materials, personal information consent form, and company introduction material consent form to Korea Bio by the 24th of this month.

 

The company introduction materials should only include only publicly available data.

 

When the domestic pharmaceutical and biohealth companies submit the required documents, Roche Asia Partnering will select companies after review.

 

Select companies will have on/offline meeting opportunities with Roche, and receive feedback related to the contents discussed.

 

Then, a select few that wish to partner with Roche will receive the opportunity to have face-to-face meetings at Roche headquarters, global branches, and subsidiary research institutes.

 

As collaboration areas, Roche suggested immunology, oncology, neurological disorders, research and development technology, personalized digital healthcare, rare diseases, and infectious diseases.

 

If approved, the collaboration will be carried out with its Genentech Research Center, Roche Innovation Center Basel, Roche’s Shanghai Innovation Center, Global Product Development Department, and Product Strategy Department, etc.

 

The industry believes that Korea BIO's open innovation project will be an opportunity for domestic companies to receive feedback from multinational pharmaceutical companies on their direction of pipeline research, further required research, and the marketability of their candidate substances.

 

Starting with Bayer in 2021, Korea BIO had held open innovation partnering events with Boehringer Ingelheim, Novartis, French Healthcare Club, and CJ in the same year.